Retrospective analysis of concurrent chemoradiation with triweekly cisplatin plus 5-fluorouracil versus weekly cisplatin in cervical cancer

Kenzo Sonoda; Hideaki Yahata; Akimasa Ichinoe; Kaoru Okugawa; Eisuke Kaneki; Yoshiaki Kawano; Hironori Kenjo; Tatsuhiro Ohgami; Hiroshi Yagi; Saiji Ohga; Kaori Asai; Katsumasa Nakamura; Hiroshi Honda; Kiyoko Kato

Retrospective analysis of concurrent chemoradiation with triweekly cisplatin plus 5-fluorouracil versus weekly cisplatin in cervical cancer

Kenzo Sonoda, Hideaki Yahata, Akimasa Ichinoe, Kaoru Okugawa, Eisuke Kaneki, Yoshiaki Kawano, Hironori Kenjo, Tatsuhiro Ohgami, Hiroshi Yagi, Saiji Ohga, Kaori Asai, Katsumasa Nakamura, Hiroshi Honda, Kiyoko Kato

Research output: Contribution to journal › Review article › peer-review

3 Citations (Scopus)

Abstract

Background/Aim: Concurrent chemoradiation (CCRT) is the standard treatment for locally advanced cervical cancer. The purpose of the study was to compare the outcomes of triweekly cisplatin plus 5-fluorouracil and weekly cisplatin regimens. Patients and Methods: We retrospectively reviewed data from 91 patients with stage IB1-IVA cervical cancer. Results: Out of 91 patients, 48 received triweekly CCRT and 43 received weekly CCRT. For triweekly CCRT, patients received a median of two chemotherapy cycles and median total doses of cisplatin and 5-fluorouracil were 210 mg/body and 8,525 mg/body, respectively. For weekly CCRT, patients received a median of five chemotherapy cycles and the median total dose of cisplatin was 252 mg/body. No statistically significant differences in overall survival or progression-free survival were noted between the two groups. Conclusion: Both triweekly CCRT and weekly CCRT appear to have similar efficacy for cervical cancer patients, but the toxicities were better tolerable in weekly CCRT.

Original language	English
Pages (from-to)	3447-3454
Number of pages	8
Journal	Anticancer research
Volume	35
Issue number	6
Publication status	Published - Jun 1 2015

All Science Journal Classification (ASJC) codes

Oncology
Cancer Research

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Cite this

@article{3895bb9c9ea6495e8b0199a86d967256,

title = "Retrospective analysis of concurrent chemoradiation with triweekly cisplatin plus 5-fluorouracil versus weekly cisplatin in cervical cancer",

abstract = "Background/Aim: Concurrent chemoradiation (CCRT) is the standard treatment for locally advanced cervical cancer. The purpose of the study was to compare the outcomes of triweekly cisplatin plus 5-fluorouracil and weekly cisplatin regimens. Patients and Methods: We retrospectively reviewed data from 91 patients with stage IB1-IVA cervical cancer. Results: Out of 91 patients, 48 received triweekly CCRT and 43 received weekly CCRT. For triweekly CCRT, patients received a median of two chemotherapy cycles and median total doses of cisplatin and 5-fluorouracil were 210 mg/body and 8,525 mg/body, respectively. For weekly CCRT, patients received a median of five chemotherapy cycles and the median total dose of cisplatin was 252 mg/body. No statistically significant differences in overall survival or progression-free survival were noted between the two groups. Conclusion: Both triweekly CCRT and weekly CCRT appear to have similar efficacy for cervical cancer patients, but the toxicities were better tolerable in weekly CCRT.",

author = "Kenzo Sonoda and Hideaki Yahata and Akimasa Ichinoe and Kaoru Okugawa and Eisuke Kaneki and Yoshiaki Kawano and Hironori Kenjo and Tatsuhiro Ohgami and Hiroshi Yagi and Saiji Ohga and Kaori Asai and Katsumasa Nakamura and Hiroshi Honda and Kiyoko Kato",

year = "2015",

month = jun,

day = "1",

language = "English",

volume = "35",

pages = "3447--3454",

journal = "Anticancer research",

issn = "0250-7005",

publisher = "International Institute of Anticancer Research",

number = "6",

}

TY - JOUR

T1 - Retrospective analysis of concurrent chemoradiation with triweekly cisplatin plus 5-fluorouracil versus weekly cisplatin in cervical cancer

AU - Sonoda, Kenzo

AU - Yahata, Hideaki

AU - Ichinoe, Akimasa

AU - Okugawa, Kaoru

AU - Kaneki, Eisuke

AU - Kawano, Yoshiaki

AU - Kenjo, Hironori

AU - Ohgami, Tatsuhiro

AU - Yagi, Hiroshi

AU - Ohga, Saiji

AU - Asai, Kaori

AU - Nakamura, Katsumasa

AU - Honda, Hiroshi

AU - Kato, Kiyoko

PY - 2015/6/1

Y1 - 2015/6/1

N2 - Background/Aim: Concurrent chemoradiation (CCRT) is the standard treatment for locally advanced cervical cancer. The purpose of the study was to compare the outcomes of triweekly cisplatin plus 5-fluorouracil and weekly cisplatin regimens. Patients and Methods: We retrospectively reviewed data from 91 patients with stage IB1-IVA cervical cancer. Results: Out of 91 patients, 48 received triweekly CCRT and 43 received weekly CCRT. For triweekly CCRT, patients received a median of two chemotherapy cycles and median total doses of cisplatin and 5-fluorouracil were 210 mg/body and 8,525 mg/body, respectively. For weekly CCRT, patients received a median of five chemotherapy cycles and the median total dose of cisplatin was 252 mg/body. No statistically significant differences in overall survival or progression-free survival were noted between the two groups. Conclusion: Both triweekly CCRT and weekly CCRT appear to have similar efficacy for cervical cancer patients, but the toxicities were better tolerable in weekly CCRT.

AB - Background/Aim: Concurrent chemoradiation (CCRT) is the standard treatment for locally advanced cervical cancer. The purpose of the study was to compare the outcomes of triweekly cisplatin plus 5-fluorouracil and weekly cisplatin regimens. Patients and Methods: We retrospectively reviewed data from 91 patients with stage IB1-IVA cervical cancer. Results: Out of 91 patients, 48 received triweekly CCRT and 43 received weekly CCRT. For triweekly CCRT, patients received a median of two chemotherapy cycles and median total doses of cisplatin and 5-fluorouracil were 210 mg/body and 8,525 mg/body, respectively. For weekly CCRT, patients received a median of five chemotherapy cycles and the median total dose of cisplatin was 252 mg/body. No statistically significant differences in overall survival or progression-free survival were noted between the two groups. Conclusion: Both triweekly CCRT and weekly CCRT appear to have similar efficacy for cervical cancer patients, but the toxicities were better tolerable in weekly CCRT.

UR - http://www.scopus.com/inward/record.url?scp=84931448208&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84931448208&partnerID=8YFLogxK

M3 - Review article

C2 - 26026109

AN - SCOPUS:84931448208

SN - 0250-7005

VL - 35

SP - 3447

EP - 3454

JO - Anticancer research

JF - Anticancer research

IS - 6

ER -

Retrospective analysis of concurrent chemoradiation with triweekly cisplatin plus 5-fluorouracil versus weekly cisplatin in cervical cancer

Abstract

All Science Journal Classification (ASJC) codes

UN SDGs

Other files and links

Fingerprint

Cite this